• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Systemic therapy in advanced hepatocellular carcinoma.

作者信息

Ahn Joseph C, Tran Nguyen H, Yang Ju Dong

机构信息

Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.

Department of Medical Oncology, Mayo Clinic, Rochester, MN, USA.

出版信息

Clin Mol Hepatol. 2023 Apr;29(2):516-519. doi: 10.3350/cmh.2023.0051. Epub 2023 Feb 20.

DOI:10.3350/cmh.2023.0051
PMID:36800697
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10121316/
Abstract
摘要

相似文献

1
Systemic therapy in advanced hepatocellular carcinoma.晚期肝细胞癌的全身治疗
Clin Mol Hepatol. 2023 Apr;29(2):516-519. doi: 10.3350/cmh.2023.0051. Epub 2023 Feb 20.
2
[New progress in the first-line treatment of advanced hepatocellular carcinoma].[晚期肝细胞癌一线治疗的新进展]
Zhonghua Gan Zang Bing Za Zhi. 2024 Feb 20;32(2):173-179. doi: 10.3760/cma.j.cn501113-20231114-00193.
3
[Clinical advances in targeted therapy and immunotherapy for hepatocellular carcinoma].[肝细胞癌靶向治疗与免疫治疗的临床进展]
Zhonghua Gan Zang Bing Za Zhi. 2019 Nov 20;27(11):834-837. doi: 10.3760/cma.j.issn.1007-3418.2019.11.005.
4
[Status and challenges of neoadjuvant immunotherapy for hepatocellular carcinoma].[肝细胞癌新辅助免疫治疗的现状与挑战]
Zhonghua Wai Ke Za Zhi. 2023 Jan 1;61(1):7-12. doi: 10.3760/cma.j.cn112139-20220819-00361.
5
Hepatocellular carcinoma in the era of immunotherapy.免疫治疗时代的肝细胞癌
Curr Probl Cancer. 2018 Jan-Feb;42(1):40-48. doi: 10.1016/j.currproblcancer.2017.10.007. Epub 2017 Nov 15.
6
Management of people with early- or very early-stage hepatocellular carcinoma: an attempted network meta-analysis.早期或极早期肝细胞癌患者的管理：一项网络荟萃分析尝试
Cochrane Database Syst Rev. 2017 Mar 28;3(3):CD011650. doi: 10.1002/14651858.CD011650.pub2.
7
Evolution of Systemic Therapy in Advanced Hepatocellular Carcinoma.晚期肝细胞癌系统治疗的进展。
Surg Oncol Clin N Am. 2024 Jan;33(1):73-85. doi: 10.1016/j.soc.2023.06.003. Epub 2023 Aug 12.
8
Selective internal radiation therapies for unresectable early-, intermediate- or advanced-stage hepatocellular carcinoma: systematic review, network meta-analysis and economic evaluation.不可切除的早期、中期或晚期肝细胞癌的选择性内放射治疗：系统评价、网络荟萃分析和经济评估。
Health Technol Assess. 2020 Sep;24(48):1-264. doi: 10.3310/hta24480.
9
Immunotherapy for NAFLD and NAFLD-related hepatocellular carcinoma.免疫疗法治疗非酒精性脂肪性肝病和非酒精性脂肪性肝病相关肝细胞癌。
Front Endocrinol (Lausanne). 2023 Mar 20;14:1150360. doi: 10.3389/fendo.2023.1150360. eCollection 2023.
10
Combination locoregional and systemic therapies in hepatocellular carcinoma.肝细胞癌的局部区域与全身联合治疗
Lancet Gastroenterol Hepatol. 2025 Apr;10(4):369-386. doi: 10.1016/S2468-1253(24)00247-4. Epub 2025 Feb 21.

引用本文的文献

1
Comparative effectiveness of immunotherapy versus lenvatinib in advanced hepatocellular carcinoma: A real-world analysis using target trial emulation.免疫疗法与乐伐替尼治疗晚期肝细胞癌的疗效比较：一项采用目标试验模拟的真实世界分析。
Hepatology. 2025 Mar 28. doi: 10.1097/HEP.0000000000001328.
2
An Early Increase in IL-10 and TNF-α Levels Following Atezolizumab Plus Bevacizumab Treatment Predicts Survival in Advanced Hepatocellular Carcinoma Patients: A Prospective Cohort Study.阿替利珠单抗联合贝伐单抗治疗后早期白细胞介素-10和肿瘤坏死因子-α水平升高可预测晚期肝细胞癌患者的生存：一项前瞻性队列研究
Cancers (Basel). 2024 Oct 21;16(20):3543. doi: 10.3390/cancers16203543.
3

本文引用的文献

1
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma.特瑞利木单抗联合度伐利尤单抗治疗不可切除肝细胞癌。
NEJM Evid. 2022 Aug;1(8):EVIDoa2100070. doi: 10.1056/EVIDoa2100070. Epub 2022 Jun 6.
2
Evolving therapeutic landscape of advanced hepatocellular carcinoma.晚期肝细胞癌不断演变的治疗格局。
Nat Rev Gastroenterol Hepatol. 2023 Apr;20(4):203-222. doi: 10.1038/s41575-022-00704-9. Epub 2022 Nov 11.
3
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial.
CCL5/CCR5/CYP1A1 pathway prompts liver cancer cells to survive in the combination of targeted and immunological therapies.
CCL5/CCR5/CYP1A1 通路促使肝癌细胞在靶向和免疫治疗联合治疗中存活。
Cancer Sci. 2024 Nov;115(11):3552-3569. doi: 10.1111/cas.16320. Epub 2024 Aug 25.
4
T cell-related ubiquitination genes as prognostic indicators in hepatocellular carcinoma.T 细胞相关泛素化基因作为肝细胞癌的预后指标。
Front Immunol. 2024 Jun 11;15:1424752. doi: 10.3389/fimmu.2024.1424752. eCollection 2024.
5
What should be done to reduce the discrepancy between guidelines and real-life practice for hepatocellular carcinoma in Korea?为缩小韩国肝细胞癌指南与实际临床实践之间的差异，应采取哪些措施？
Clin Mol Hepatol. 2023 Apr;29(2):332-334. doi: 10.3350/cmh.2023.0080. Epub 2023 Mar 16.
6
The prime time for management of hepatocellular carcinoma in Hong Kong.香港肝细胞癌的最佳治疗时机。
Clin Mol Hepatol. 2023 Apr;29(2):345-348. doi: 10.3350/cmh.2023.0094. Epub 2023 Mar 9.
7
Overview of Asian clinical practice guidelines for the management of hepatocellular carcinoma: An Asian perspective comparison.亚洲肝细胞癌管理临床实践指南概述：亚洲视角比较。
Clin Mol Hepatol. 2023 Apr;29(2):252-262. doi: 10.3350/cmh.2023.0099. Epub 2023 Mar 10.
卡博替尼联合阿替利珠单抗与索拉非尼治疗晚期肝细胞癌（COSMIC-312）：一项多中心、开放标签、随机、III 期临床试验。
Lancet Oncol. 2022 Aug;23(8):995-1008. doi: 10.1016/S1470-2045(22)00326-6. Epub 2022 Jul 4.
4
Randomized Phase 3 LEAP-012 Study: Transarterial Chemoembolization With or Without Lenvatinib Plus Pembrolizumab for Intermediate-Stage Hepatocellular Carcinoma Not Amenable to Curative Treatment.随机 3 期 LEAP-012 研究：经动脉化疗栓塞联合或不联合仑伐替尼加帕博利珠单抗治疗不可治愈的中期肝细胞癌。
Cardiovasc Intervent Radiol. 2022 Apr;45(4):405-412. doi: 10.1007/s00270-021-03031-9. Epub 2022 Feb 4.
5
Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma.IMbrave150研究的更新疗效和安全性数据：阿替利珠单抗联合贝伐珠单抗对比索拉非尼治疗不可切除肝细胞癌。
J Hepatol. 2022 Apr;76(4):862-873. doi: 10.1016/j.jhep.2021.11.030. Epub 2021 Dec 11.
6
BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update.BCLC 策略用于预后预测和治疗推荐：2022 年更新版。
J Hepatol. 2022 Mar;76(3):681-693. doi: 10.1016/j.jhep.2021.11.018. Epub 2021 Nov 19.
7
Radioembolisation with Y90-resin microspheres followed by nivolumab for advanced hepatocellular carcinoma (CA 209-678): a single arm, single centre, phase 2 trial.钇 90 树脂微球放射性栓塞联合纳武利尤单抗治疗晚期肝细胞癌（CA 209-678）：一项单臂、单中心、2 期临床试验。
Lancet Gastroenterol Hepatol. 2021 Dec;6(12):1025-1035. doi: 10.1016/S2468-1253(21)00305-8. Epub 2021 Oct 23.
8
Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial.多纳非尼对比索拉非尼用于不可切除或转移性肝细胞癌的一线治疗：一项随机、开放标签、平行对照的 II/III 期试验。
J Clin Oncol. 2021 Sep 20;39(27):3002-3011. doi: 10.1200/JCO.21.00163. Epub 2021 Jun 29.
9
Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.信迪利单抗联合贝伐珠单抗生物类似药（IBI305）对比索拉非尼治疗不可切除肝细胞癌（ORIENT-32）：一项随机、开放标签的2/3期研究
Lancet Oncol. 2021 Jul;22(7):977-990. doi: 10.1016/S1470-2045(21)00252-7. Epub 2021 Jun 15.
10
Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.阿帕替尼二线或后线治疗晚期肝细胞癌（AHELP）的多中心、双盲、随机、安慰剂对照、III 期临床试验
Lancet Gastroenterol Hepatol. 2021 Jul;6(7):559-568. doi: 10.1016/S2468-1253(21)00109-6. Epub 2021 May 8.